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DOI 10.1016/j.stem.2010.09.010It is widely stated that the use of reprog-
rammed pluripotent cells for clinical
regenerative medicine will require ‘‘trans-
gene-free’’ cell derivation. We propose
that patient-specific iPSCs marked with
genetic modifications should be used
in early autologous transplantation trials
to track their safety and therapeutic
performance. No reprogramming factor
genes should be present in clinical grade
iPSC lines because their reactivation,
particularly C-MYC, could induce tumors
(Nakagawa et al., 2008). Although efforts
to eliminate these transgenes with various
techniques are invaluable, it remains
unclear whether factor-free iPSCs and
ESCs are inherently safe in a clinical
context. The current expectation that
cell therapies will soon be available for
a broad spectrum of diseases through
use of transgene-free reprogrammed
cells is simplistic. In fact, to treat genetic
diseases, autologous iPSCs will have to
be genetically corrected to be of thera-
peutic value. The only data regarding the
safety of transgenes in clinical samples
come from gene therapy. In particular,
the first successful gene therapy trial for
X-SCID was compromised by leukemia
induction caused by retroviral insertions
into the LMO2 locus (Hacein-Bey-Abina
et al., 2003), although other successful
trials have escaped this outcome (Aiuti
et al., 2009). Themechanism of insertional
activation is that enhancer elements in
the LTRs of a retrovirus vector activate a
nearby oncogene promoter. By reducing
the transgene copy number, improving
vector technology and carefully screening
the transduced cells for potential geno-
toxic integration sites, gene therapy withintegrating transgenes is expected to
become safer and more effective in the
clinic.
How does the safety profile of iPSCs
generated with integrating viral vectors
compare to the cells used in the X-SCID
trial? First, clonal iPSCs can be generated
with four factors combined in one polycis-
tronic vector that integrates at a single site
in the genome of a given cell, unlike the
millions of integration sites observed in
the polyclonal cell populations used for
X-SCID gene therapy. Because clonal
iPSCs are easy to expand, any integration
site can be definitively mapped. There-
fore, proximity to genes or miRNAs with
potential tumorigenic properties can be
identified, the expression profile of sur-
rounding genes can be evaluated fol-
lowing differentiation, and the safety of
the resulting mature cells can be con-
firmed by assaying for tumorigenicity in
xenografts. Second, the reprogramming
factor genes can be deleted with Cre-lox
or other approaches to leave a solo LTR
at the identified safe integration site
known as a ‘‘safe harbor.’’ If the vector
is a self-inactivating lentivirus, this LTR
will be transcriptionally inactive and have
no enhancer elements to drive insertional
activation. Third, only one gene needs to
be transferred in gene therapy settings,
usually in nontumorigenic cell types. In
iPSCs, on the other hand, the transcrip-
tional program of the entire genome is re-
programmed to yield a teratoma-forming
cell type. Moreover, the iPSC tissue of
origin, incomplete epigenetic reorganiza-
tion resulting in partially reprogrammed
cells, and potential mutations acquired
by clonal expansion after reprogrammingCell Stem Cellmay also elicit safety related conse-
quences for iPSCs.
Because transgenes have already
been approved for cell marking and
gene therapy by regulatory agencies,
and iPSCs have an inherent tumorigenic
risk, then it would be beneficial to use
genetically modified iPSCs in clinical
settings. We propose that these trials
should be designed to permit basic
science observations regarding the fate
and function of the transplanted cells.
An NIH review of gene therapy in 1995
by Orkin and Motulsky noted that over
100 trials had failed to produce any bene-
ficial effects, and specifically recommen-
ded that clinical studies be designed to
yield useful basic information irrespective
of the clinical outcome (http://www.
nih.gov/news/panelrep.html). It is naive
to expect the first attempts at iPSC
therapies to produce immediate cures.
If autologous cells are used to derive
therapeutic iPSC lines, there will be no
means to assess whether the trans-
planted cells survived, localized, or en-
grafted to produce functional or negative
effects. No serious mouse transplanta-
tion studies are conducted with isogenic
untrackable cells. The Geron funded
human ESC trial for spinal cord injury will
use trackable cells that are genetically
distinct from the recipient. The same
arguments in favor of genetic modifica-
tions that permit cell tracking could be
applied to efforts to transdifferentiate
cells for clinical purposes, or even to
improve the evaluation of autologous
bone marrow transplantation in which
grafted cells cannot be distinguished from
endogenous cells.7, October 8, 2010 ª2010 Elsevier Inc. 429
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fications may prove useful for detecting
the progeny of iPSCs in patients. Homolo-
gous recombination-mediated correction
of mutations in patient-derived iPSCs,
or a self-inactivated solo LTR remaining
from a deleted reprogramming vector,
could yield modifications that would
be detectable by PCR, a method that
can detect one marked cell in 100,000
cells (Pan et al., 2002). This sensitivity is
sufficient to identify subtherapeutic levels
of transplanted cells and to define a tumor
origin. New generation approaches en-
able more quantitative measurements
such that detailed biodistribution studies
detecting single marked cells in tissue
samples may already be feasible. Con-
ventional transgenes that code for ex-
pressed proteins may be more practical,
by permitting in vivo cell tracking or by
serving as suicide genes to kill tumor-
forming cells. In this case, a single copy
transgene could be targeted to a safe
harbor or randomly integrated into430 Cell Stem Cell 7, October 8, 2010 ª2010a subsequently demonstrated safe site.
In comparison to the risk of one transgene
integration in iPSCs, our own neu-
rons are bombarded by novel Line1 retro-
transposon insertions, implying an inser-
tional mutagenesis load is normal in
some tissues that are candidates for
iPSC therapy (Coufal et al., 2009). Taken
together with the known genomic insta-
bility during reprogramming, novel gene
marks are a normal consequence of
generating and differentiating pluripotent
cells. In fact, the current concept of
reprogramming could evolve beyond cell
transplant applications to include in vivo
gene transfer approaches that direct
fibroblast conversion into cardiomyo-
cytes to stimulate endogenous cardiac
repair (Ieda et al., 2010). Once iPSCs
arrive at the clinic, they should not contain
any reprogramming factor transgene,
but they could retain a deleted LTR and
would further benefit from having genetic
modifications for cell tracking including
imaging, or for conditional elimination ofElsevier Inc.residual pluripotent cells or progeny
gone astray.REFERENCES
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